As with other drugs, Carvykti (ciltacabtagene autoleucel) can cause side effects, such as fever and digestive issues. If you are not able to tolerate side effects of Carvykti, talk with your ...

Despite initial caution, Carvykti's sales surged, reaching $334M in Q4 2024, driving Legend Biotech Corporation to net income and solidifying its market position. Legend's financial health is ...

The company’s flagship product, Carvykti, a CAR-T therapy for multiple myeloma, has demonstrated strong efficacy and is driving the company’s growth prospects. This comprehensive analysis ...

Net Trade Sales of CARVYKTI: $334 million in Q4 2024, a 110% increase year-over-year and a 17% increase from Q3. OUS Sales: $31 million, a 138% increase year-over-year and 15% quarter-over-quarter.

The company’s flagship product, Carvykti, a CAR-T therapy for multiple myeloma, has demonstrated strong efficacy and is driving the company’s growth prospects. This comprehensive analysis examines ...

We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as “ANI per Share”) as performance metrics. Adjusted Net Loss and ANI per Share are not defined under IFRS ...

Companies spend millions developing logos to represent a brand. Some of them have hidden meanings steeped in the history and ...

The firm updated its model to reflect quarter-over-quarter trends anticipated for Carvykti in 2025 and to moderate its 2025-plus ex-U.S. Carvykti ramp expectations. Published first on TheFly ...

Since Todd McLellan took over as coach on Dec. 28, the Detroit Red Wings have the best record in the NHL. As a result of this streak, powered by a red-hot power play, the Red Wings look poised to ...

ST. PAUL, Minn. — The Detroit Red Wings overcame a bad start with a mediocre middle – and a tall finish. Simon Edvinsson scored twice Tuesday at Xcel Energy Center as the Wings rallied to a ...

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...